Literature DB >> 21490682

Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells.

J Leja1, D Yu, B Nilsson, L Gedda, A Zieba, T Hakkarainen, G Åkerström, K Öberg, V Giandomenico, M Essand.   

Abstract

We have previously described the oncolytic adenovirus, Ad(CgA-E1A-miR122), herein denoted Ad5(CgA-E1A-miR122) that selectively replicates in and kills neuroendocrine cells, including freshly isolated midgut carcinoid cells from liver metastases. Ad5(CgA-E1A-miR122) is based on human adenovirus serotype 5 (Ad5) and infects target cells by binding to the coxsackie-adenovirus receptor (CAR) and integrins on the cell surface. Some neuroendocrine tumor (NET) and neuroblastoma cells express low levels of CAR and are therefore poorly transduced by Ad5. However, they often express high levels of somatostatin receptors (SSTRs). Therefore, we introduced cyclic peptides, which contain four amino acids (FWKT) and mimic the binding site for SSTRs in the virus fiber knob. We show that FWKT-modified Ad5 binds to SSTR₂ on NET cells and transduces midgut carcinoid cells from liver metastases about 3-4 times better than non-modified Ad5. Moreover, FWKT-modified Ad5 overcomes neutralization in an ex vivo human blood loop model to greater extent than Ad5, indicating that fiber knob modification may prolong the systemic circulation time. We conclude that modification of adenovirus with the FWKT motif may be beneficial for NET therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21490682     DOI: 10.1038/gt.2011.54

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  14 in total

1.  Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.

Authors:  Di Yu; Chuan Jin; Justyna Leja; Nadim Majdalani; Berith Nilsson; Fredrik Eriksson; Magnus Essand
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

Review 2.  Update in the Therapy of Advanced Neuroendocrine Tumors.

Authors:  Inbal Uri; Shani Avniel-Polak; David J Gross; Simona Grozinsky-Glasberg
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

Review 3.  New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.

Authors:  Joakim Crona; David Taïeb; Karel Pacak
Journal:  Endocr Rev       Date:  2017-12-01       Impact factor: 19.871

Review 4.  The Landscape and Clinical Application of the Tumor Microenvironment in Gastroenteropancreatic Neuroendocrine Neoplasms.

Authors:  Shuaishuai Xu; Chanqi Ye; Ruyin Chen; Qiong Li; Jian Ruan
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

5.  Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors.

Authors:  Reese W Randle; Scott A Northrup; S Joseph Sirintrapun; Douglas S Lyles; John H Stewart
Journal:  Surgery       Date:  2013-08-22       Impact factor: 3.982

Review 6.  Drug Development in Neuroendocrine Tumors: What Is on the Horizon?

Authors:  Alejandro Garcia-Alvarez; Jorge Hernando Cubero; Jaume Capdevila
Journal:  Curr Treat Options Oncol       Date:  2021-03-30

7.  CD123 targeting oncolytic adenoviruses suppress acute myeloid leukemia cell proliferation in vitro and in vivo.

Authors:  G Li; X Li; H Wu; X Yang; Y Zhang; L Chen; X Wu; L Cui; L Wu; J Luo; X Y Liu
Journal:  Blood Cancer J       Date:  2014-03-21       Impact factor: 11.037

Review 8.  Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm.

Authors:  Mingxu Guan; Gaetano Romano; Roberta Coroniti; Earl E Henderson
Journal:  J Exp Clin Cancer Res       Date:  2014-11-01

9.  The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.

Authors:  Su-Chen Li; Cécile Martijn; Tao Cui; Ahmed Essaghir; Raúl M Luque; Jean-Baptiste Demoulin; Justo P Castaño; Kjell Öberg; Valeria Giandomenico
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

10.  Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors.

Authors:  Su-Chen Li; Ahmed Essaghir; Cécile Martijn; Ricardo V Lloyd; Jean-Baptiste Demoulin; Kjell Oberg; Valeria Giandomenico
Journal:  Mod Pathol       Date:  2013-01-18       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.